Francisco Javier Guenaga

Title: Francisco Javier Guenaga: Innovator in HIV-1 Vaccine Development

Introduction

Francisco Javier Guenaga is a notable inventor based in New York, NY (US). He has made significant contributions to the field of HIV research, particularly in the development of innovative vaccine candidates. With a total of 2 patents, his work focuses on creating effective immunogens for combating HIV-1.

Latest Patents

Guenaga's latest patents include groundbreaking advancements in HIV-1 envelope glycoproteins. The first patent, titled "N-glycan deleted HIV-1 envelope glycoprotein trimers," relates to novel HIV-1 envelope glycoproteins that can be utilized as immunogens for vaccines. This invention encompasses the preparation and purification of immunogenic compositions formulated into vaccines. The second patent, "Soluble HIV-1 envelope glycoprotein trimers," similarly focuses on the development of HIV-1 envelope glycoproteins for use as vaccine immunogens and for the identification of broad neutralizing antibodies.

Career Highlights

Throughout his career, Guenaga has worked with prominent organizations in the field of HIV research. He has been associated with the International Aids Vaccine Initiative and the Scripps Research Institute, where he has contributed to advancing vaccine research and development.

Collaborations

Guenaga has collaborated with esteemed colleagues, including Viktoriya Dubrovskaya and Richard Wyatt, to further his research efforts in HIV vaccine development.

Conclusion

Francisco Javier Guenaga's innovative work in the field of HIV-1 vaccine development highlights his commitment to addressing global health challenges. His patents and collaborations reflect his significant contributions to the scientific community.